Capital Flow Monitor · Sponsors · CIK 1829255
Halia Therapeutics, Inc.
3900 N. Traverse Mountain Blvd., Lehi, UT, 84043 · 801-842-1652
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$20.0M
Sold
$3.5M
% sold
17.4%
Investors
9
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | D ·current | 506(b) | $20.0M | $3.5M | 17.4% | 9 | EDGAR ↗ |
| 2025-07-16 | D | 506(b) | $20.0M | $337K | 1.7% | 5 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Jeffrey Burton — Executive Officer, Lehi, UT
- David Bearss — Director, Lehi, UT
-
David Checketts — Director, Lehi, UT
2 other raises
- John S.K. Kauwe — Director, Lehi, UT
- Gary B. Sabin — Director, Lehi, UT
- Mary Beckerle — Director, Lehi, UT
- Preston Campbell — Director, Lehi, UT
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.